• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019 - Product Image

Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019

  • ID: 2155709
  • June 2012
  • 87 pages
  • GlobalData

Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The report identifies the key trends shaping and driving the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Post-Traumatic Stress Disorder (PTSD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Post-Traumatic READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Posttraumatic Stress Disorder Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.2.1 Prevalence
2.2.2 Pharmacoeconomic Burden
2.2.3 Quality of Life (QoL)
2.3 Etiology and Pathophysiology
2.3.2 Risk Factor
2.3.3 Co-morbidities
2.4 Signs and Symptoms
2.4.1 Re-experiencing Symptoms
2.4.2 Avoidance symptoms
2.4.3 Hyperarousal Symptoms
2.5 Diagnosis
2.5.1 Diagnosis Criteria
2.5.2 Psychobiologic Approaches
2.6 Treatment and Management Options
2.6.1 Non-pharmacological Treatment
2.6.2 Pharmacological Treatment
2.6.3 The US
2.6.4 Europe
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance
3 Posttraumatic Stress Disorder Therapeutics - Market Characterization
3.1 Overview
3.2 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Global
3.3 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Global
3.4 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - The US
3.5 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - The US
3.6 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - France
3.7 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - France
3.8 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Germany
3.9 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Germany
3.10 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Italy
3.11 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Italy
3.12 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Spain
3.13 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Spain
3.14 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - The UK
3.15 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - The UK
3.16 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Japan
3.17 PTSD Therapeutics Market Forecast (2011-2019) - Japan
3.18 Drivers and Barriers for the Posttraumatic Stress Disorder Therapeutics Market
3.18.1 Drivers for the Posttraumatic Stress Disorder Therapeutics Market
3.18.2 Barriers for the Posttraumatic Stress Disorder Therapeutics Market
3.19 Opportunity and Unmet Need Analysis
3.20 Key Takeaway
4 Posttraumatic Stress Disorder Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Posttraumatic Stress Disorder Therapeutics Market
4.3.1 Selective Serotonin Reuptake Inhibitors (SSRIs)
4.3.2 Paxil (paroxetine)
4.3.3 Zoloft (sertraline)
4.3.4 Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
4.3.5 Atypical Antipsychotics
4.4 Key Takeaway
5 Posttraumatic Stress Disorder Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Posttraumatic Stress Disorder Therapeutics Pipeline - Pipeline by Phases of Development
5.3.1 Posttraumatic Stress Disorder Therapeutics - Phase III Pipeline
5.3.2 Posttraumatic Stress Disorder Therapeutics - Phase II Pipeline
5.3.3 Posttraumatic Stress Disorder Therapeutics - Phase I Pipeline
5.3.4 Posttraumatic Stress Disorder Therapeutics - Pre-clinical Pipeline
5.3.5 Posttraumatic Stress Disorder Therapeutics - Discovery Pipeline
5.3.6 Technology Trends Analytic Framework
5.4 Posttraumatic Stress Disorder Therapeutics Market -Pipeline by Mechanism of Action
5.5 Molecule Profile for Promising Drugs under Clinical Development
5.5.1 Avlocardyl (propranolol)
5.6 Key Takeaway
6 Posttraumatic Stress Disorder Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Posttraumatic Stress Disorder Therapeutics Clinical Trials
7 Posttraumatic Stress Disorder Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Posttraumatic Stress Disorder Therapeutics: Implications for Future Market Competition
8 Posttraumatic Stress Disorder Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Synosia Therapeutics/Biotie Therapies Corp.
8.2.2 Columbia Northwest Pharmaceuticals
8.2.3 Marinus Pharmaceuticals, Inc.
8.2.4 Nanotherapeutics, Inc.
9 Posttraumatic Stress Disorder Therapeutics - Licensing and Partnership Deals
10 Posttraumatic Stress Disorder Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Bibliography
10.4 Research Methodology
10.4.1 Coverage
10.4.2 Secondary Research
10.4.3 Forecasting
10.4.4 Primary Research
10.4.5 Expert Panel Validation
10.5 Contact Us
10.6 Disclaimer

1.1 List of Tables
Table 1: Prevalence Rates of Posttraumatic Stress Disorder by Country/Region
Table 2: Frequency (%) of Lifetime Co-morbidities in Patients with Posttraumatic Stress Disorder-
Table 3: DSM-IV Diagnostic Criteria for Posttraumatic Stress Disorder
Table 4: ICD-10 Diagnostic Criteria for Posttraumatic Stress Disorder
Table 5: Medications for Posttraumatic Stress Disorder - Indications and Contraindications
Table 6: Posttraumatic Stress Disorder Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 7: Posttraumatic Stress Disorder Therapeutics Market, Global, Forecast ($m), 2011-2019
Table 8: Posttraumatic Stress Disorder Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 9: Posttraumatic Stress Disorder Therapeutics Market, The US, Forecasts ($m), 2011-2019
Table 10: Posttraumatic Stress Disorder Therapeutics Market, France, Revenue ($m), 2006-2011
Table 11: Posttraumatic Stress Disorder Therapeutics Market, France, Forecasts ($m), 2011-2019
Table 12: Posttraumatic Stress Disorder Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 13: Posttraumatic Stress Disorder Therapeutics Market, Germany, Forecasts ($m), 2011-2019
Table 14: Posttraumatic Stress Disorder Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 15: Posttraumatic Stress Disorder Therapeutics Market, Italy, Forecasts ($m), 2011-2019
Table 16: Posttraumatic Stress Disorder Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 17: Posttraumatic Stress Disorder Therapeutics Market, Spain, Forecasts ($m), 2011-2019
Table 18: Posttraumatic Stress Disorder Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 19: Posttraumatic Stress Disorder Therapeutics Market, The UK, Forecasts ($m), 2011-2019
Table 20: Posttraumatic Stress Disorder Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 21: Posttraumatic Stress Disorder Therapeutics Market, Japan, Forecasts ($m), 2011-2019
Table 22: SSRIs Used for Treatment of Posttraumatic Stress Disorder
Table 23: SNRIs used in treatment of Posttraumatic Stress Disorder
Table 24: Posttraumatic Stress Disorder Therapeutics - Phase III Pipeline, 2012
Table 25: Posttraumatic Stress Disorder Therapeutics - Phase II Pipeline, 2012
Table 26: Posttraumatic Stress Disorder Therapeutics - Phase I Pipeline, 2012
Table 27: Posttraumatic Stress Disorder Therapeutics - Pre-clinical Pipeline, 2012
Table 28: Posttraumatic Stress Disorder Therapeutics - Discovery Pipeline, 2011
Table 29: Posttraumatic Stress Disorder Therapeutics - Clinical Trials by Country, 2011
Table 30: Posttraumatic Stress Disorder Therapeutics -- Clinical Trials by Phase, 2011
Table 31: Posttraumatic Stress Disorder Therapeutics - Clinical Trials by Status
Table 32: Posttraumatic Stress Disorder Therapeutics - Overall Sponsors, 2011
Table 33: Posttraumatic Stress Disorder Therapeutics - Most Prominent Sponsors, 2011
Table 34: Posttraumatic Stress Disorder Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 35: Biotie Therapies, CNS Pipeline 2012
Table 36: Columbia Northwest Pharmaceuticals, CNS Pipeline 2012
Table 37: Marinus Pharmaceuticals, Inc., CNS Pipeline 2012
Table 38: Nanotherapeutics, Inc., CNS Pipeline 2012
Table 39: Posttraumatic Stress Disorder Therapeutics, Global, Deals, 2010-2012

1.2 List of Figures
Figure 1: Time Course and Posttraumatic Stress Disorder Subtypes
Figure 2: Key Opinion Leader Insights, Prevalence of Posttraumatic Stress Disorder in the US, Germany and the UK
Figure 3: Posttraumatic Stress Disorder Prevalence in Adults in the US
Figure 4: Posttraumatic Stress Disorder Treatment Rate in the US
Figure 5: Factors Associated with the Development of Posttraumatic Stress Disorder
Figure 6: Genetic Factors Associated in Patients with Posttraumatic Stress Disorder
Figure 7: HPA-axis Pathway, Stress Responses
Figure 8: Posttraumatic Stress Disorder, Stress Responses
Figure 9: Neuroendocrine Features in Patients with Posttraumatic Stress Disorder
Figure 10: Neurotransmitter Features in Patients with Posttraumatic Stress Disorder
Figure 11: Neuroanatomic Features in Patients with Posttraumatic Stress Disorder
Figure 12: Co-morbidities Associated with Posttraumatic Stress Disorder
Figure 13: Symptoms of Posttraumatic Stress Disorder
Figure 14: Key Opinion Leader Insights, Diagnosis of Posttraumatic Stress Disorder in the US, Germany and the UK
Figure 15: Key Opinion Leader Insights, Guidelines for Posttraumatic Stress Disorder in the US, Germany and the UK
Figure 16: Algorithm for the Diagnosis and Treatment of Posttraumatic Stress Disorder
Figure 17: The US:Treatment Guideline for Posttraumatic Stress Disorder
Figure 18: Key Opinion Leader Insights, Treatment of Posttraumatic Stress Disorder in the US, Germany and the UK
Figure 19: Referral Pathway for Posttraumatic Stress Disorder
Figure 20: Key Opinion Leader Insights, Referral Pathway for Posttraumatic Stress Disorder in the US, Germany and the UK
Figure 21: Posttraumatic Stress Disorder Therapeutics Market, Global, Revenue ($m), 2006-2011
Figure 22: Posttraumatic Stress Disorder Therapeutics Market, Global, Forecast ($m), 2011-2019
Figure 23: Posttraumatic Stress Disorder Therapeutics Market, the US, Revenue ($m), 2006-2011
Figure 24: Posttraumatic Stress Disorder Therapeutics Market, The US, Forecast ($m), 2011-2019
Figure 25: Posttraumatic Stress Disorder Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 26: Posttraumatic Stress Disorder Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 27: Posttraumatic Stress Disorder Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 28: Posttraumatic Stress Disorder Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 29: Posttraumatic Stress Disorder Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 30: Posttraumatic Stress Disorder Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 31: Posttraumatic Stress Disorder Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 32: Posttraumatic Stress Disorder Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 33: Posttraumatic Stress Disorder Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 34: Posttraumatic Stress Disorder Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 35: Posttraumatic Stress Disorder Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 36: Posttraumatic Stress Disorder Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 37: Key Opinion Leader Insights, Current Unmet Needs for Posttraumatic Stress Disorder in the US, Germany and the UK
Figure 38: Opportunity and Unmet Need for Posttraumatic Stress Disorder Therapeutics Market
Figure 39: Key Opinion Leader Insights, Limitations of the Currently Available Treatment Options for Posttraumatic Stress Disorder in the US, Germany and the UK
Figure 40: Posttraumatic Stress Disorder Therapeutics - Strategic Competitor Assessment, 2011
Figure 41: Key Opinion Leader Insights, Research for Future Treatment Options for Posttraumatic Stress Disorder in the US, Germany and the UK
Figure 42: Posttraumatic Stress Disorder Therapeutics - Pipeline by Phase of Development, 2012
Figure 43: Posttraumatic Stress Disorder Therapeutics - Technology Trends Analytics Framework, 2012
Figure 44: Posttraumatic Stress Disorder Therapeutics - Technology Trends Analytics Framework - Description, 2012
Figure 45: Posttraumatic Stress Disorder Therapeutics - Pipeline by Mechanism of Action, 2012
Figure 46: Clinical Trial Details of Avlocardyl (Propranolol)
Figure 47: Posttraumatic Stress Disorder Therapeutics - Clinical Trials by Country, 2011
Figure 48: Posttraumatic Stress Disorder Therapeutics - Clinical Trials by Phase, 2011
Figure 49: Posttraumatic Stress Disorder Therapeutics - Clinical Trials by Status, 2011
Figure 50: Posttraumatic Stress Disorder Therapeutics - Overall Sponsors, 2012
Figure 51: Posttraumatic Stress Disorder Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 52: Posttraumatic Stress Disorder Therapeutics Market, Drivers and Restraints 2011
Figure 53: Implications for Future Market Competition in Posttraumatic Stress Disorder Market, 2011
Figure 54: Posttraumatic Stress Disorder Therapeutics Market - Pipeline by Company, 2012
Figure 55: GlobalData Market Size Estimation
Figure 56: GlobalData Market Forecasting Model

Future Post-Traumatic Stress Treatments May Disappoint Growing Number of Trauma Victims.

Members of the armed forces and victims of abuse taking medication for post-traumatic stress disorder (PTSD) are unlikely to see any revolutionary changes to their drug treatment in the near future, despite growing numbers, according to a new report by healthcare experts GlobalData.

The new report* indicates that the current research and development undertaken by drug companies is not likely offer the novel, safe and long-term treatment options sufferers are seeking, or move treatment away from the well-established antidepressants that current PTSD therapies greatly rely on.

GlobalData’s research indicates that the PTSD therapeutics market is currently served by two FDA-approved selective serotonin reuptake inhibitors (SSRIs), Zoloft and Paxil, and various off-label generic drugs with a low cost of therapy. Sufferers are often prescribed established antidepressant therapies alongside non-pharmacological treatment options such as cognitive behavioral therapy.

The approved drugs only have moderate efficacy and safety profiles, which sometimes drives the medical practitioners towards the use of behavioral therapies.Many patients with PTSD also suffer from co-morbid psychiatric disorders such as depression, alcohol and drug abuse, and other anxiety disorders, which significantly reduces the choice of appropriate drugs available. Consequently, there is a high unmet need for new drugs with novel mechanisms of action that could potentially treat patients with co-morbidities.

A recent market dip following the patent expiries of Paxil (US/Europe: 2007/2006) and Zoloft (US/Europe: 2006) demonstrated the demand for a new choice of PTSD medications, especially as predicted growth in the patient population and increasing awareness among physicians is set to drive up the future unmet need.

Despite this, GlobalData’s recent pipeline research suggests that only a few pharmaceutical companies are presently researching into new and advanced treatment options for PTSD, creating a weak developmental pipeline. The majority of the 16 molecules currently in development are being sponsored by universities and academic institutions, giving the potential new drugs less financial backing for the development process, while the late-stage pipeline consists of only two molecules that are both university-sponsored and without novel mechanisms of action. This means that no new revolutionary treatments are due to hit the market within the next decade.

GlobalData estimates that the global PTSD therapeutics market was worth $1,388.3m in 2011, following a decline at a negative compound annual growth rate (CAGR) of 1.9% during 2006-2011. It is expected to grow at a CAGR of 3.2% to reach $1,782.9m by 2019, due to an increased patient population.

*Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019

This report identifies the key trends shaping and driving the global post-traumatic stress disorder (PTSD) therapeutics market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global PTSD therapeutics sector.

Synosia Therapeutics/Biotie Therapies Corp.
Columbia Northwest Pharmaceuticals
Marinus Pharmaceuticals, Inc.
Nanotherapeutics, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos